ASGCT Congress 2020
Our Contribution
Viroclinics will shed light on the topic: “The Ferret As An Animal Model To Study Respiratory Syncytial Virus Infection, Transmission And Countermeasures” on Day 2 of the conference [April 8th, at 12:10]. We will discuss the following topics:
- Demonstration of efficient transmission of human respiratory syncytial virus (HRSV) fromimmunocompromised ferrets to both immunocompromised and immunocompetent ferrets.
- Research findings were collected by applying several assays including Sequencing, PCR, Virus Culture/Titration. Furthermore, histo pathological changes of respiratory tissues from donor and contact ferrets were demonstrated by standard and immunohistochemistry.
- A high transmission rate of HRSV was found and more …
We are looking forward to sharing our latest insights with you during ASGCT Congress 2020
Speaker
Dr Koert Stittelaar, PhD, General Manager Viroclinics Xplore
Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the National Institute of Public Health and University of Utrecht working on Neisseria meningitidis-specific T cell responses. Koert defended his PhD thesis in 2001: “Vaccination against Measles” at the Erasmus University Rotterdam. His start at Viroclinics Biosciences boosted the Preclinical Service activities within the company. He gained expertise in the field of influenza virus and RSV intervention strategy research and is now mainly concerned with containment of highly pathogenic viruses, model development and project acquisition like polio virus related projects. Koert has authored many publications.
Contact Speaker
This form is currently undergoing maintenance. Please try again later.
OUR LATEST NEWS
Launching our new business unit Viroclinics Xellerate
Viroclinics-DDL, today announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.
REPROCELL and VIROCLINICS-DDL Renew Collaboration Agreement in Clinical Research
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
ENPICOM and Viroclinics-DDL receive joint MIT R&D ZH subsidy subsidy to accelerate and improve antibody and vaccine discovery and development
Partnership combines Viroclinics-DDL’s diagnostic and high-throughput sequencing experience with ENPICOM’s expertise in bioinformatics and immunomics.
